Promising results have been announced from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells. Of the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.
from Top Health News – ScienceDaily http://bit.ly/2gMvBoP
from Tumblr http://bit.ly/2gMx4LY
No comments:
Post a Comment